---
title: "Amgen’s Tavneos Main Approval Study Retracted by New England Journal of Medicine"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291182021.md"
description: "A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, putting the drug’s continued sales at risk, according to Bloomberg."
datetime: "2026-06-29T19:06:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291182021.md)
  - [en](https://longbridge.com/en/news/291182021.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291182021.md)
---

# Amgen’s Tavneos Main Approval Study Retracted by New England Journal of Medicine

A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, putting the drug’s continued sales at risk, according to Bloomberg.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio](https://longbridge.com/en/news/293257595.md)
- [Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings](https://longbridge.com/en/news/291188646.md)
- [Amgen taps research firm to reassess Tavneos data](https://longbridge.com/en/news/289522929.md)
- [Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight](https://longbridge.com/en/news/289602804.md)
- [Amgen (AMGN) Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap](https://longbridge.com/en/news/291728558.md)